youtube_live
Q3 2026 earnings • in 3 days
See detailschevron_right
AVTR:NYSE
Avantor Inc
$17.29
arrow_upward
+0.85%(+0.15) 1D
$17.50
arrow_upward
+1.21% (+0.21)bedtimeAfter hours
Closed: Oct 23, 4:00:07 PM GMT-4 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AVTR...
Open
$17.10
High
$17.32
Low
$16.90
Mkt. cap
11.69B
Avg. vol.
9.44M
Volume
7.87M
52-wk high
$17.45
52-wk low
$7.26
EPS
-$0.85
Beta
0.94
Shares outstanding
676.36M
No. of employees
14K
Open
$17.10
High
$17.32
Low
$16.90
Mkt. cap
11.69B
Avg. vol.
9.44M
Volume
7.87M
52-wk high
$17.45
52-wk low
$7.26
EPS
-$0.85
Beta
0.94
Shares outstanding
676.36M
No. of employees
14K
News stories
From web sources and news partners
Yahoo Finance
·
1 day ago
How Organic Growth Recovery Will Impact Avantor Stock Investors
GuruFocus
·
3 days ago
Is Avantor Inc (AVTR) Overvalued After 3.9% Rally? GF Value Says
Profile
Avantor, Inc. is an American biotechnology, chemicals, and pharmaceutical company headquartered in Radnor, Pennsylvania. Established in 1904 as J.T. Baker, the company changed its name to Avantor in 2010. Avantor went public in 2019 and is now listed on the New York Stock Exchange under the symbol “AVTR”. Wikipedia
About Avantor Inc
CEO-
Employees13.5K
Founded1904
HeadquartersRadnor Township, Pennsylvania, United States
SectorHealth care
Websiteavantorsciences.com
Analyst ratings
Based on 13 analysts giving stock ratings to AVTR in the past 3 months
Hold
Buy
0
Hold
12
Sell
1
12-month forecast
Based on 13 Wall Street analysts offering 12 month price targets for AVTR in the last 3 months.
Highest
Current $17.29
$17.00 (-1.68%)
Average
$14.96 (-13.48%)
Lowest
$13.00 (-24.81%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Eve Burstein Bernstein | Hold | Reiterated | $15.50 | -10.4% | 10/19/2026 |
Casey Woodring J.P. Morgan | Hold | Maintained | $15.00 | -13.2% | 10/16/2026 |
Daniel Brennan TD Cowen | Hold | Maintained | $17.00 | -1.7% | 10/13/2026 |
Kallum Titchmarsh Morgan Stanley | Hold | Reiterated | $15.00 | -13.2% | 10/13/2026 |
Lu Li Bank of America Securities | Hold | Maintained | $17.00 | -1.7% | 10/09/2026 |
Unknown Analyst Bank of America Securities | Hold | Maintained | $17.00 | -1.7% | 10/09/2026 |
Luke Sergott Barclays | Sell | Maintained | $15.00 | -13.2% | 10/07/2026 |
Evan Stampler Wells Fargo | Buy | Maintained | $16.00 | -7.5% | 09/21/2026 |
Matt Larew William Blair | Hold | Reiterated | - | - | 09/21/2026 |
Unknown Analyst UBS | Hold | Initiated | $16.00 | -7.5% | 09/08/2026 |
Doug Schenkel UBS | Hold | Maintained | $16.00 | -7.5% | 09/09/2026 |
Vijay Kumar Evercore ISI | Hold | Maintained | $14.00 | -19% | 07/30/2026 |
Justin Bowers Deutsche Bank | Hold | Maintained | $13.00 | -24.8% | 07/30/2026 |
Daniel Arias Stifel Nicolaus | Hold | Reiterated | $15.00 | -13.2% | 07/30/2026 |
Brandon Couillard Wells Fargo | Buy | Maintained | $16.00 | -7.5% | 07/30/2026 |
Dan Leonard RBC Capital | Hold | Maintained | $14.00 | -19% | 07/29/2026 |
Tycho Peterson Jefferies | Hold | Upgraded | $13.00 | -24.8% | 07/29/2026 |
Patrick B Donnelly Citi | Hold | Maintained | $11.00 | -36.4% | 07/08/2026 |
Michael Polark Wolfe Research | Sell | Reiterated | $7.00 | -59.5% | 06/01/2026 |
Unknown Analyst RBC Capital | Hold | Initiated | $9.00 | -47.9% | 05/14/2026 |
Catherine Ramsey Schulte Robert W. Baird | Buy | Maintained | $11.00 | -36.4% | 02/12/2026 |
Michael Ryskin Bank of America Securities | Hold | Reiterated | $11.00 | -36.4% | 02/11/2026 |
Next call in 3 days
Wed, Oct 28, 2:00 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / $0.21
Revenue / Est. (USD)
- / 1.64B
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 1.62B | 1.66B | 1.58B | 1.69B |
Cost of goods sold | 1.10B | 1.14B | 1.08B | 1.16B |
Cost of revenue | 1.10B | 1.14B | 1.08B | 1.16B |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 388.80M | 354.70M | 401.70M | 415.80M |
Operating expense | 388.80M | 354.70M | 401.70M | 415.80M |
Total operating expenses | 1.49B | 1.49B | 1.48B | 1.57B |
Operating income | 137.70M | 169.20M | 99.00M | 121.20M |
Other non operating income | 700.00K | -7.00M | - | 100.00K |
EBT including unusual items | -689.50M | 80.80M | 55.50M | 81.20M |
EBT excluding unusual items | 95.70M | 120.10M | 56.10M | 81.80M |
Income tax expense | 22.30M | 28.40M | 12.20M | 43.10M |
Effective tax rate | -3.23% | 35.15% | 21.98% | 53.08% |
Other operating expenses | - | - | - | - |
Net income | -711.80M | 52.40M | 43.30M | 38.10M |
Net profit margin | -43.84% | 3.15% | 2.74% | 2.25% |
Earnings per share | 0.22 | 0.22 | 0.17 | 0.21 |
Interest and investment income | 11.90M | 11.40M | 10.50M | 10.30M |
Interest expense | -58.00M | -53.40M | -53.40M | -49.70M |
Net interest expenses | -46.10M | -42.00M | -42.90M | -39.40M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 242.20M | 272.50M | 204.00M | 226.80M |
Gain or loss from assets sale | - | 5.10M | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1